At the time of writing, Iovance Biotherapeutics Inc [IOVA] stock is trading at $1.91, up 4.37%. An important factor to consider is whether the stock is rising or falling in short-term value. The IOVA shares have gain 6.70% over the last week, with a monthly amount drifted -37.99%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on May 16, 2025, when UBS downgraded its rating to a Neutral but kept the price target unchanged to $2 for it. Previously, Truist downgraded its rating to Hold on May 12, 2025. On May 09, 2025, downgrade downgraded it’s rating to Mkt Perform. UBS started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 24, 2024. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $10 on July 29, 2024. Goldman started tracking with a Buy rating for this stock on November 20, 2023, and assigned it a price target of $12. In a note dated September 18, 2023, Barclays reiterated an Overweight rating on this stock and revised its target price from $40 to $18.
For the past year, the stock price of Iovance Biotherapeutics Inc fluctuated between $1.64 and $12.51. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $1.91 at the most recent close of the market. An investor can expect a potential return of 109.42% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
According to Iovance Biotherapeutics Inc [NASDAQ:IOVA], the company’s sales were 212.68M for trailing twelve months, which represents an 6798.46% jump. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -1.88%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Iovance Biotherapeutics Inc [NASDAQ:IOVA] has a current ratio of 4.18. On the other hand, the Quick Ratio is 3.64, and the Cash Ratio is 1.4. Considering the valuation of this stock, the price to sales ratio is 3.00, the price to book ratio is 0.83.
Transactions by insiders
Recent insider trading involved Vogt Frederick G, Interim CEO & General Counsel, that happened on May 14 ’25 when 25000.0 shares were purchased. Director, Maynard Ryan D completed a deal on Nov 12 ’24 to sell 50000.0 shares. Meanwhile, Director Maynard Ryan D bought 50000.0 shares on Nov 12 ’24.
